Ctxr stock forecast technical chart watchers highlight that

Technical chart watchers highlight that CTXR’s MACD line crossed above the signal line, supporting the CTXR stock forecast for continued short-term gains. This classical indicator aligns with recent upticks in sector ETF inflows. Ascendis, the first stock we’ll look at, is a company that is in the process of building a marketable drug program based on its unique technology-development platform. This platform is dubbed TransCon, a portmanteau shortening of transient conjugation. Using the platform, a flexible technology that makes use of advanced chemistry, Ascendis can design drug candidates that work by linking the therapeutic agent to an inert carrier compound. The platform is capable of designing new drugs, with novel therapeutics and equally novel delivery mechanisms, that can meet unmet needs in multiple diseases. This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.  Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma and Citius Oncology, are: the potential impact of the reverse split on the bid price of the Company's common stock; Citius Pharma's ability to regain compliance with and continue to meet Nasdaq's continued listing standards; our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; risks related to research using our assets but conducted by third parties; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our SEC filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission ("SEC") filings which are available on the SEC's website at www.sec.gov , including in Citius Pharma's Annual Report on Form 10-K for the year ended September 30, 2023 , filed with the SEC on December 29, 2023 , as updated by our subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Traders analyzing CTXR stock forecast are focusing on the $0.95–$1.05 consolidation range. A sustained breakout on above-average volume could trigger algorithmic buying, common in small-cap momentum trades.